Scalper1 News
Adaptimmune Therapeutics has filed for an initial public offering, adding another company to one of the hottest sectors in the biotech field. U.K.-based Adaptimmune Therapeutics plans to raise up to $150 million and list on the Nasdaq under the ticker ADAP. Adaptimmune is a clinical-stage biopharmaceutical company focused on cancer immunotherapy products based on its T-cell receptor platform. T-cells are a type of white blood cell. Immunotherapy Scalper1 News
Scalper1 News